Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis.

Inclusion Criteria: * Participants were diagnosed with atopic dermatitis (AD) for at least 6 months. * Participants with an Investigator's Global Assessment (IGA) score of 2 to 3 at screening and baseline. * Participants with body surface area (BSA) of AD involvement, excluding the scalp, face, and intertriginous areas, of 3% to 20% at screening and baseline. * BMI of 18.0-30.0 kg/m2, with body weight ≥ 50 kg for man and ≥ 40 kg for woman. * Be willing to comply with the study lifestyle restraints, e.g., no washing of the administered area within 6 hours of study drug administration, no sweaty exercise. Exclusion Criteria: * Participants with a physical condition which, in the Investigator´s opinion, might interfere with the assessment of atopic dermatitis or expose the patient to an unacceptable risk by study participation. * Participants with current evidence of any acute skin infection with a history of recurrent or chronic severe skin infection. * Participants with known allergies to components or excipients of the test drug. * Participants who are pregnant, nursing, or planning a pregnancy during the study period. * Systemic immunosuppressive or immunomodulating drugs (eg, oral or injectable corticosteroids, mycophenolate mofetil, PDE4 inhibitor) used for atopic dermatitis within 4 weeks or 5 half-lives of baseline (whichever is longer). * Participants with the following hematologic abnormities at screening: * Leukocytes \< 3.0 × 10\^9/L. * Neutrophils \< lower limit …